anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapeutic compositions, useful as local an sthetic agents, comprise an aqueous solution containing, in synergistic combination, a soluble procaine salt and a soluble butethamine salt, so proportioned that there is present in the mixture one to three units of weight of procaine per unit weight of butethamine. The salts used are those with mineral acids or with water-soluble organic carboxylic acids, but preferably the hydrochlorides.  The compositions, which are said to be less toxic than compositions containing the equivalent concentrations of the individual components separately, by virtue of their ability to migrate into surrounding tissue near the situs of injection, may be used for infiltration an s-thesia rather than only nerve-block an sthesia as known hitherto with preparations of procaine or butethamine.  The results of toxicity tests disclosed, indicate that a combination of 2 per cent procaine hydrochloride with 1 per cent or 1.25 per cent butethamine hydrochloride for subcutaneous injection to white mice, produces a toxicity indistinguishable from a 2 per cent procaine hydrochloride solution alone yet gives an an sthetic para equivalent to a 3 1/3 per cent or a 3.6 per cent procaine hydrochloride solution, respectively. Preferred compositions contain the butethamine salt in an amount within the range of 0.25 to 2 per cent by weight and the procaine salt in an amount substantially equal to 2 per cent by weight, based on the total weight of the solution.  A vasoconstrictive sympathomimelic amine such as epinephrine, ephidrine, phenylephrine or laevo-arterenol, in an amount less than 0.02 per cent by weight of the solution may also be incorporated in the compositions.
Understanding speech in noisy settings is harder for hearing-impaired (HI) people than for normal-hearing (NH) people, even when speech is audible. This is often attributed to hearing loss altering the neural encoding of temporal and/or spectral speech cues. Here, we investigated whether this difference may also be due to an impaired ability to adapt to background noise. For 25 adult hearing-aid users with sensorineural hearing loss, speech reception thresholds (SRTs) were measured for natural and tone-vocoded words embedded in speech-shaped noise (SSN). The stimuli were preceded or not by a 1-second adapting SSN precursor. Adaptation was calculated as the difference in SRT between the two precursor conditions. Corresponding data for 28 NH listeners were taken from a previously published study. SRTs were worse for HI listeners, confirming that hearing loss diminishes access to speech acoustic cues. Furthermore, noise adaptation was negatively correlated with the age-controlled hearing loss both for natural (rho=-0.56, N = 52, p < 0.001) and vocoded (rho=-0.45, N = 39, p = 0.002) words. Impaired adaptation contributed up to 10% of the SRT loss in HI listeners. We conclude that HI listeners suffer from poorer speech in noise recognition not only because of impaired access to speech acoustic cues but also because they are less able to adapt to background noise.
The present invention relates to dye compounds represented by Formulae I and II, which are described in the specification. The dye compounds of the present invention have markedly improved quantum yields and emit strong fluorescence compared to existing cyanine dyes. Due to these advantages, the dye compounds of the present invention can find applications in various fields, for example, as probes for various biological systems where optical imaging is required. Particularly, the dye compounds of the present invention can be used as mitotrackers capable of labeling and tracking mitochondria. Therefore, the dye compounds of the present invention can be used to quantitatively image mitochondria in live tissues and cells. Furthermore, the dye compounds of the present invention can be applied as pH probes for measuring the pH of live cells.
PURPOSE: To obtain a wound-healing agent containing a thrombomodulin-like protein as an active ingredient, having an effect for stimulating the growth or multiplication of cells at a damaged tissue site, improved in the effect and high in safety. CONSTITUTION: This wound-healing agent contains a thrombomodulin-like (TM- like) protein as an active ingredient. The TM-like protein is preferably e.g. a protein having an amino acid sequence of the formula. The TM-like protein can be produced by a genetic engineering technology. The employment of a human cell growth factor in addition to the TM-like protein gives larger healing and growth-stimulating effects. The human cell growth factor is preferably human insulin-like cell growth factor-1, human epithelial cell growth factor, etc. The wound-healing agent is preferably prepared in the form of an injection agent or a percutaneous absorption agent. When administered as the injection agent, the TM-like protein is preferably administered as a dose of 0.1-100μg/kg/d.  When administered as the percutaneous absorption agent, the TM-like protein is preferably used in a concentration of 0.01-100μg/ml.
The CATCH Study includes a two-year UG3 Planning Phase and a four-year UH3 Implementation Phase. In the UH3 Implementation Phase, we will first conduct a cluster randomized implementation trial to test the effectiveness and implementation of a team-based care strategy for hypertension control among patients with hypertension in 40 clinics from Colombia and Jamaica (20 in each country). Twenty clinics will be randomized to the team-based care intervention and 20 to provider training intervention. A total of 1,680 patients (42 per clinic) with uncontrolled hypertension will be recruited into the study and followed for 18 months for effectiveness and implementation outcomes. A post-intervention study visit will take place 6 months after the end of the 18-month intervention to evaluate the sustainability of the implementation strategies. We will subsequently conduct a pre- and post- scale-up comparison study to implement the team-based care strategy in all remaining public primary care clinics that provide chronic disease management in Jamaica and primary care clinics in the seven participating departments in Colombia. A pre- and post- scale-up comparison design will be used to assess barriers and implementation outcomes before and 12 months after the scale-up intervention at the clinic, primary care physician, nurse/pharmacist, and community health worker (CHW) levels.
We plan to recruit 20 patients, men with coronary artery disease, for this single center, interventional trial with the Probiotic-GoodBelly followed by Vancomycin. The study includes 6 total visits. Subjects who pass a phone screen will be invited to a screening visit for study eligibility (Visit 1) Informed consent will be reviewed; a unique study number will be assigned once written informed consent is obtained (no subject will be assigned more than 1 allocation number); relevant participant medical history will be recorded including currently prescribed medications; anthropometric measurements will be taken (height, weight, and waist circumference in metric units) and blood pressure will be recorded (measured in triplicate and averaged). Subjects will be allowed to take their blood pressure medication on the morning of their screening visit, but not the mornings of any of the other study visits to limit the acute influence of these medications on endothelial function. If the potential participant qualifies for the study, he will return 1 week after the screen for a study visit(Visit 2) where he will turn in his stool sample, undergo initial tests of endothelial function and receive 3 week supply of GoodBelly Probiotic. After 3 weeks he will have to return (Visit 3) for another 3 week supply of his probiotic. After a total of 6 weeks of taking the probiotic he will have to return (Visit 4) with his stool sample. He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function. During Visit 4, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers. If he agrees to the optional Vancomycin study. He will return after 4 weeks for (Visit 5). He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function. At Visit 5, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers. He will then be given a 10 day supply of vancomycin. After 10 days he will return (Visit 6) with his stool sample. At Visit 6, endothelial function will determined by brachial artery reactivity testing . His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers.
Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
Polycystic ovarian syndrome (PCOS) is a complex and multifactorial condition characterized by endocrinological, reproductive, metabolic, and biochemical abnormalities, affecting 12% to 21% of reproductive-aged females. It has emerged as a significant global public health concern. However, variations in diagnostic criteria and patient selection have led to considerable discrepancies in the absolute prevalence of PCOS and its temporal trends. Previous studies have examined ovarian volume and blood flow indices in both obese and non-obese females with PCOS, albeit employing different criteria for obesity classification. Notably, none have compared these parameters across normal weight, overweight, and obese PCOS females. Therefore, the current study aims to explore the impact of obesity on body composition and ovarian Doppler parameters within distinct PCOS phenotypes. An additional objective is to assess correlations between anthropometric, body composition, and ovarian Doppler parameters and the prevalence of PCOS symptoms.
The invention relates to an external medicine for treating herpes zoster and belongs to the technical field of pharmaceuticals. An external medicine for treating herpes zoster is characterized by being composed of the following traditional Chinese medicines (by weight): 2-5 parts of coptidis rhizome, 2-5 parts of cortex phellodendri, 2-5 parts of realgar, 3-6 parts of honeysuckle flower, 2-4 parts of common cnidium fruit, 1-3 parts of borneol and 2-4 parts of rhizoma paridis. The external medicine for treating herpes zoster is prepared by the following steps: mixing the above seven traditional Chinese medicines, putting the mixed traditional Chinese medicines into a container and adding water and decocting, and filtering a liquid medicine after boiling for 15-20 min. Application method of the external medicine: the liquid medicine is used daily to scrub herpes affected parts three to five times a day. The formula of the invention has effects of promoting circulation and removing stasis, draining toxin and expelling decay, clearing away heat and toxic materials and invigorating qi and promoting blood circulation, can improve microcirculation of tissues around wound surface and speed up regional blood flow, and simultaneously can promote remaining epithelial cell tissue growth, remove slough and promote growth of tissue regeneration, repair injured nerves, expel virus in body, smooth venation and qi-blood and stop pain. The external medicine of the invention has a good treatment effect.
778. Schmidt, C. Jan. 12, 1910, [Convention date]. Drawings to Specification. Drinking-vessels; jugs.-Consists in a material for jugs or tumblers prepared by mixing radio-active substance with a material such as clay or loam, which, when subjected to a burning process, binds the mass into a solid insoluble whole. The material is rendered porous by the addition of sawdust, which is driven off during the burning process. The interior of the vessel may be left unglazed to present a porous surface.
The present invention relates to the formation of nanoconjugates exhibiting antitumour activity, mainly against advanced prostate cancer, but without excluding others. The nanoconjugates are formed from dendritic systems (dendrimers or dendrons) and neuropeptides. The dendritic molecules mainly have a carbosilane structure with ammonium groups on the periphery. The peptides are preferably from the glucagon/secretin family (e.g.VIP, GHRH, PACAP). The combination of these two systems leads to a nanoconjugate with anticarcinogenic properties that differ from those of their individual precursors. The antitumour activity is reflected in the growth inhibition and death of tumour cells in advanced prostate cancer (PC3) and, in addition, said nanoconjugates favour cell adhesion and prevent tumour cell migration processes, in other words metastasis processes.
This invention provides fused heterocycles having the formula: in which R 1  is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 2  is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 3  is a member selected from the group consisting of H 1  C 1 -C 6  substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 4  is a member selected from OH and O -  X + , in which X +  is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. The index n is an integer from 1 to 4. Formulae A, B.
Participants will receive cevostamab, IV, in combination with elranatamab, SC, with step-up dosing of each drug in pre-phase following which they will receive elranatamab, at the assigned dose as a SC injection until disease progression or unacceptable toxicity. Participants will also receive cevostamab at the assigned dose as IV infusion until disease progression or unacceptable toxicity or up to 1 year on treatment, whichever occurs first.
Cigarette smoking is associated with worse clinical outcomes in patients with chronic hepatitis B (CHB) infection, but the effects on hepatitis B surface antigen (HBsAg) seroclearance are unclear. This study aimed to investigate the effect of active smoking on HBsAg seroclearance (SC) and its impact on peripheral blood lymphocytes in patients with CHB infection. Longitudinal follow-up data was retrieved in 7833 antiviral-treated CHB subjects identified from a centralised electronic patient record database (Part 1). Phenotypic analysis of peripheral blood mononuclear cells (PBMCs) from 27 CHB-infected patients (6 active smokers; 13 with SC) was performed by flow cytometry to assess programmed death-1 (PD-1) expression and proportion of regulatory T cells (CD4+CD25+CD127lo). Effector function of HBV-specific T cells was examined by comparing granzyme B (GZMB) and transforming growth factor beta (TGFβ) production in undepleted PBMCs and Treg-depleted PBMCs after 7 days in vitro stimulation with HBV envelope protein overlapping peptides (Part 2). Over a median follow-up of 5 years, smoking was associated with lower probability of SC (aHR 0.70, 95% CI 0.57-0.87). PD-1 expression was increased in CD4+ T cells, CD8+ T cells and CD20+ B cells among smokers compared to non-smokers and positively correlated with pack years (all p < 0.05). Treg depletion led to partial functional recovery of HBV-specific T cells, with significantly bigger magnitude in smokers (p = 0.0451, mean difference = 4.68%) than non-smokers (p = 0.012, mean difference = 4.2%). Cigarette smoking is associated with lower chance of HBsAg seroclearance, higher PD-1 expression on lymphocytes, and impairment of effector functions of HBV-specific T cells in CHB.
PURPOSE: Marfan Syndrome (MFS) is a connective tissue disorder that affects skeletal, ocular, pulmonary, cardiovascular, and central nervous systems. Symptoms may lead to diminished quality of life (QoL) in individuals with MFS compared with healthy individuals. Currently, there is little evidence regarding the impact of MFS on voicing and QoL. This study examined perceptions of voicing difficulties and QoL among persons with MFS.
METHOD: A total of 356 participants with a self-reported diagnosis of MFS completed the Quality-of-Life Index (QLI) and voice handicap index-10 (VHI-10) and provided medication regime.
RESULTS: Some degree of voice handicap was reported by a majority of participants. Analyses assessing correlations between responses to the VHI-10, QLI scores, and reported medications were conducted. Specific medications and responses on the VHI-10 were significantly associated with QLI scores. Multiple regression analyses revealed that a summed VHI-10 score was the strongest predictor of QLI satisfaction, QLI importance, and overall QLI.
CONCLUSIONS: The findings of the current study suggest that individuals with MFS may experience self-perceived phonatory dysfunction which impact QoL. Specific classes of drugs may also be associated with reported voice handicap and QoL satisfaction in MFS. These findings have implications for physicians and clinicians who work with individuals with MFS.
Twice per week exercise program, 45 minutes duration for 12 weeks conducted in a community site (assisted living residence). Participants also attended a 3o minute fall prevention education session once per week. The Standard intervention consisted of a fall prevention exercise program designed for community-dwelling older adults. Exercises focussed on balance, leg strength, walking and mobility exercises designed to decrease fall risk.
Physical pain and negative emotions represent two distinct drinking motives that contribute to harmful alcohol use. Proactive avoidance, in contrast, can reduce consumption in response to these motives but appears to be impaired in those with problem drinking. Despite such evidence, proactive avoidance and its underlying neural deficits have not been assessed experimentally. How these deficits inter-relate with drinking motives to influence alcohol use also remains unclear. The current study leveraged neuroimaging data in forty-one problem and forty-one social drinkers who performed a probabilistic learning go/nogo task featuring proactive avoidance of painful outcomes. We identified the brain responses to proactive avoidance and contrasted the neural correlates of drinking to avoid negative emotions vs. physical pain. Behavioral results confirmed proactive avoidance deficits in problem drinking individuals' learning rate and performance accuracy, both which were associated with greater alcohol use. Imaging findings in the problem drinking group showed that negative emotions as a drinking motive predicted attenuated right anterior insula activation during proactive avoidance. In contrast, physical pain motive predicted reduced right putamen response. These regions' activations as well as functional connectivity with the somatomotor cortex also demonstrated a negative relationship with drinking severity and positive relationship with proactive avoidance performance. Path modeling further delineated the pathways through which physical pain and negative emotions influenced the neural and behavioral measures of proactive avoidance. Taken together, the current findings provide experimental evidence for proactive avoidance deficits in alcohol misuse and establish the link between their neural underpinnings and drinking behavior.
This study evaluated physical activity interventions designed for individuals with visual impairments and sought to guide health intervention scientists aiming to promote physical activity in this demographic. We delved into the specifics of participants' visual impairments, intervention features, accommodation approaches, and replicability prospects. The search spanned four databases, namely PubMed, CINAHL, SportDiscus, and Scopus, providing a wide scope and diversity of potential studies. There were no restrictions on publication years. We reviewed 13 studies, totaling 15 interventions. A consensus on visual-impairment definitions remains elusive, and the intervention dosages displayed variability. Notably, 66.7% (n = 7) integrated behavior-change techniques to amplify physical activity levels. Multiple studies employed audio descriptions as an accommodation method. While most studies provided adequate information for potential replication, detailed study protocols were frequently absent. It is essential for developed interventions to be persistently evaluated and fine-tuned to optimize results.
A hair-styling appliance 100 comprises a hollow container body 101 which has an opening 102 at one end. An attachment 103 is releasably connectable to the body 101. The attachment 103 has a secondary fluid reservoir 111, communicating with the body 101, the reservoir having apertures 112 therein. A foam application 113 is fixed adjacent the apertures 112. The appliance 100 may be used to transfer perm solution to a head of hair. To this end, in use, the applicator 113 of the appliance 100 is urged against the hair of a person at a desired position, and fluid flows under gravity and/or due to the body 101 being squeezed, from the body 101 and through the applicator, before being transferred to the head. The apparatus may allow solutions used in hair styling to be accurately and controllably transferred to a person's hair, and may be modified to apply a tint solution. <IMAGE>
The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.